Search Result

Results for "

integrin α4β1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (37) Apoptosis (3) Caspase (1) Drug Isomer (1) ERK (1) FAK (1) MMP (1) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (2) Src (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (2) Inflammation/Immunology (23) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Targets Recommended: Integrin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134130

Integrin modulator 1 2 Publications Verification	Integrin	Inflammation/Immunology
Integrin modulator 1 is a potent and selective **α4β1 integrin agonist, with an IC₅₀** of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC₅₀ of 12.9 nM .

HY-107589

BIO5192 2 Publications Verification	Integrin	Inflammation/Immunology
BIO5192 is a selective and potent integrin *α4β1* (VLA-4) inhibitor (K_d<10 pM). BIO5192 selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .

HY-108831A

Natalizumab (Anti-CD49d) 3 Publications Verification AN100226; BG00002	Integrin	Inflammation/Immunology Cancer
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .

HY-15770

TR-14035 Maximum Cited Publications 6 Publications Verification	Integrin	Inflammation/Immunology
TR-14035 is a orally active dual **α₄β₇/α₄β₁ integrin antagonist, with IC₅₀** s of 7 nM and 87 nM for α₄β₇ and α₄β₁, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .

HY-14951

Firategrast Maximum Cited Publications 6 Publications Verification SB 683699	Integrin	Neurological Disease
Firategrast (SB 683699) is an orally active and specific **α4β1/α4β7 integrin** antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .

HY-P3522

REDV	Integrin	Cardiovascular Disease
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the **integrin alpha 4 beta 1(α4β1)**. REDV can be used for the research of cell adhesion. REDV is used to study the effects of gene vectors containing REDV on cells .

HY-124290

Carotegrast methyl AJM300	Integrin	Inflammation/Immunology
Carotegrast methyl (AJM300) is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl prevents the development of colitis in mice .

HY-N2587

Irigenin	Integrin Apoptosis	Cancer
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and *α4β1* integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-P2267

LDV 1 Publications Verification	Integrin	Others
LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells .

HY-75385

Zaurategrast ethyl ester CDP323; UCB1184197	Integrin	Inflammation/Immunology
Zaurategrast ethyl ester (CDP323), the ethyl ester proagent of CT7758 , is a *α4β1/α4β7* integrin antagonist used for the treatment of inflammatory and autoimmune disorders .

HY-108831

Natalizumab 3 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .

HY-175287

α5β1 integrin agonist-2	Integrin	Cancer
α5β1 integrin agonist-2 (Compound 2) is a selective α5β1 integrin agonist (EC₅₀ = 45.98 nM). α5β1 integrin agonist-2 induces integrin activation. α5β1 integrin agonist-2 is applicable to the research of leukemia .

HY-129453

BOP sodium	Integrin	Inflammation/Immunology
BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with K_d values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins .

HY-107589A

BIO5192 hydrate 2 Publications Verification	Integrin	Inflammation/Immunology
BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (K_d<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .

HY-138542

RO0270608	Integrin	Inflammation/Immunology
RO0270608, the active metabolite of R411, is a dual **alpha4beta1-alpha4beta7 (α4β1/α4β7)** integrin antagonist. Antiinflammatory activity .

HY-14190

Valategrast R-411 free base	Integrin	Inflammation/Immunology
Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .

HY-139702

α5β1 integrin agonist-1	Integrin Apoptosis Caspase	Cancer
α5β1 integrin agonist-1 is an α5β1 integrin agonist, with an EC₅₀ of 1.5 nM. α5β1 integrin agonist-1 inhabits α4β1 integrin (IC₅₀ = 2.99 μM) in Jurkat/VCAM-1 adhesion assayα5β1 integrin agonist-1 induces concentration-dependent apoptosis and activates the caspase 3/7 pathway in α5β1 integrin-expressing K562 cancer cells. α5β1 integrin agonist-1 can be used for the study of cancer .

HY-P1188

LDV-FITC	Integrin	Cancer
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the **α4β1 integrin with high affinity (K_d*: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn ²⁺ respectively). LDV-FITC can be used to detect α4β1* integrin affinity .

HY-P11445

GREDVGC	Integrin	Cancer
GREDVGC is a peptide. GREDVGC can mimic VCAM-1 for binding to **integrin α4β1**. GREDVGC can be used for the research of cancer .

HY-175286

α4β1 antagonist-1	Integrin ERK	Inflammation/Immunology Cancer
α₄β₁ antagonist-1 (Compound 4) is a highly selective **α₄β₁ integrin antagonist (IC₅₀*=15 nM). α4β1* antagonist-1 inhibits integrin-mediated cell adhesion and ERK1/2 signaling activation. α₄β₁ antagonist-1 also exhibits partial agonism toward α_Mβ₂ integrin (EC₅₀=23 nM). α₄β₁ antagonist-1 is promising for research of chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis) and cancers .

HY-75385A

Zaurategrast ethyl ester sulfate CDP323 sulfate; UCB1184197 sulfate	Integrin	Inflammation/Immunology
Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester proagent of CT7758 , is a *α4β1/α4β7* integrin antagonist used for the treatment of inflammatory and autoimmune disorders .

HY-123164

IVL 745 XRP 1745A	Integrin	Inflammation/Immunology
IVL 745 (XRP 1745A) is a very late antigen 4 (VLA-4, **integrin α4β1**) antagonist. IVL 745 reduces the airway inflammatory response of sensitized rats and sheep. IVL 745 can be used for airway inflammation and asthma research .

HY-159179

α4 integrin receptor antagonist 3	Integrin	Inflammation/Immunology
α4 integrin receptor antagonist 3 (Compound 11) is an orally active α₄integrin receptor antagonist. α4 integrin receptor antagonist 3 can inhibit the adhesion of K562 cells mediated by the interaction between *α₄β₁/VCAM-1* and α₄β₇/MAdCAM-1, with IC₅₀ values of 130 nM and 2 nM, respectively. α4 integrin receptor antagonist 3 has the potential to be used in the study of dextran sulfate sodium (DSS) colitis mouse model .

HY-119142

CP-664511	Integrin	Inflammation/Immunology
CP-664511 is an orally active and potent **α4β1 integrin antagonist with anti-inflammatory effects (IC₅₀*=0.52 nM). CP-664511 inhibits the interaction between α4β1* and vascular cell adhesion molecule-1 (VCAM-1), significantly reducing eosinophil infiltration into lung tissue. CP-664511 is promising for research of asthma and allergic airway diseases .

HY-123802

BIO7662	Integrin	Cancer
BIO7662 is a specific *α4β1* antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions .

HY-P3522A

REDV TFA	Integrin	Cancer
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the **integrin alpha 4 beta 1(α4β1)**. REDV TFA can be used for the research of cell adhesion .

HY-P1188A

LDV-FITC TFA	Integrin	Cancer
LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the **α4β1 integrin with high affinity (K_d*: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn ²⁺ respectively). LDV-FITC TFA can be used to detect α4β1* integrin affinity .

HY-124290A

Carotegrast methyl hydrochloride AJM300 hydrochloride	Integrin	Inflammation/Immunology
Carotegrast methyl (AJM300) hydrochloride is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl hydrochloride, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl hydrochloride prevents the development of colitis in mice .

HY-136214

R-BC154 acetate	Integrin	Inflammation/Immunology Cancer
R-BC154 acetate is a selective fluorescent α₉β₁ integrin antagonist. R-BC154 acetate acts as a useful high affinity, activation dependent integrin probe, which can be used to investigate α9β1 and α4β1 integrin binding activity .

HY-14189

Valategrast hydrochloride R-411	Integrin	Inflammation/Immunology
Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and α4β7 dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .

HY-N2587R

Irigenin (Standard)	Reference Standards Integrin Apoptosis	Cancer
Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-122585

proMMP-9 inhibitor-3c	MMP Src FAK	Cancer
proMMP-9 inhibitor-3c (compound 3c) is a potent proMMP-9 inhibitor. proMMP-9 inhibitor-3c is specific for binding to the proMMP-9 hemopexin-like domain (K_d=320 nM). proMMP-9 inhibitor-3c disruption of MMP-9 homodimerization prevents association of proMMP-9 with both α4β1 integrin and CD44 and results in the dissociation of EGFR. This disruption results in decreased phosphorylation of Src and its downstream target proteins focal adhesion kinase (FAK) and paxillin (PAX) .

HY-122023

TBC3486	Integrin	Inflammation/Immunology Cancer
TBC3486 is a highly selective integrin *α4β1* inhibitor. TBC3486 acts as a chemosensitizer to enhance the sensitivity of leukemia cells to chemotherapy. TBC3486 exhibits efficacy in preclinical models of integrin α4-dependent inflammatory and autoimmune diseases, including a mouse model of autoimmune encephalomyelitis. TBC3486 can be used for the research of precursor B-cell acute lymphoblastic leukemia .

HY-114225

TBC-4746	Integrin	Neurological Disease Inflammation/Immunology
TBC-4746 is a *α4β1/α4β7* integrin antagonist. TBC-4746 can be used in the research of asthma and multiple sclerosis .

HY-107589R

BIO5192 (Standard)	Reference Standards Integrin	Inflammation/Immunology
BIO5192 (Standard) is the analytical standard of BIO5192 (HY-107589). This product is intended for research and analytical applications. BIO5192 is a selective and potent integrin α4β1 (VLA-4) inhibitor (K_d<10 pM). BIO5192 selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .

HY-14190A

(rac)-Valategrast (rac)-R-411 free base	Drug Isomer	Others
(rac)-Valategrast ((rac)-R-411 free base) is a racemic compound of Valategrast (HY-14190). Valategrast is a potent, orally active dual antagonist of integrin *α4β1* (VLA-4) and α4β7. Valategrast may be used in research on chronic obstructive pulmonary disease (COPD) and asthma.

HY-171216

GW559090	Integrin	Neurological Disease
GW559090 is a selective, competitive, and high-affinity α4 integrin antagonist with a K_d of 0.19 nM for *α4β1. GW559090 can effectively block the binding of α4β1* to vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with IC₅₀ values of 7.72 and 8.04 nM. GW559090 also inhibits the interaction between α4β7 and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) (IC₅₀ = 23 nM). GW559090 can inhibit inflammatory infiltration in the eyes, repair the corneal barrier and restore the function of goblet cells. GW559090 can be used for research of Sjögren's syndrome associated dry eye .

HY-136692

HMR 1031	Integrin	Inflammation/Immunology
HMR 1031 is a very late antigen-4 (VLA4, i.e., integrin *α4β1) inhibitor, with IC₅₀* values of 0.7 nM and 0.3 nM against VLA-4/VCAM-1 and VLA-4/fibronectin, respectively. HMR 1031 blocks allergen-induced airway responses and airway inflammation in mouse and sheep models. HMR 1031 can be used in asthma-related research .

HY-P3335

SU015 DOTA-RGDfK dimer	Integrin Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
SU015 (DOTA-RGDfK dimer) is a Integrin α_vβ₅ and α_vβ₃ antagonist. SU015 exhibits comparable affinity for α_vβ₅ and α_vβ₃, with relatively higher potency and specificity compared to other integrins. SU015 inhibits α_vβ₃-mediated cell adhesion to fibrinogen, α_vβ₃-mediated adhesion of activated platelets to osteopontin, and α_vβ₅-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with ⁹⁰Y (i.e., RP697) or ¹⁷⁷Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .

Cat. No.	Product Name	Target	Research Area

HY-P3522

REDV	Integrin	Cardiovascular Disease
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the **integrin alpha 4 beta 1(α4β1)**. REDV can be used for the research of cell adhesion. REDV is used to study the effects of gene vectors containing REDV on cells .

HY-P2267

LDV 1 Publications Verification	Integrin	Others
LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells .

HY-P1188

LDV-FITC	Integrin	Cancer
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the **α4β1 integrin with high affinity (K_d*: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn ²⁺ respectively). LDV-FITC can be used to detect α4β1* integrin affinity .

HY-P11445

GREDVGC	Integrin	Cancer
GREDVGC is a peptide. GREDVGC can mimic VCAM-1 for binding to **integrin α4β1**. GREDVGC can be used for the research of cancer .

HY-P3522A

REDV TFA	Integrin	Cancer
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the **integrin alpha 4 beta 1(α4β1)**. REDV TFA can be used for the research of cell adhesion .

HY-P1188A

LDV-FITC TFA	Integrin	Cancer
LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the **α4β1 integrin with high affinity (K_d*: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn ²⁺ respectively). LDV-FITC TFA can be used to detect α4β1* integrin affinity .

HY-P3335

SU015 DOTA-RGDfK dimer	Integrin Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
SU015 (DOTA-RGDfK dimer) is a Integrin α_vβ₅ and α_vβ₃ antagonist. SU015 exhibits comparable affinity for α_vβ₅ and α_vβ₃, with relatively higher potency and specificity compared to other integrins. SU015 inhibits α_vβ₃-mediated cell adhesion to fibrinogen, α_vβ₃-mediated adhesion of activated platelets to osteopontin, and α_vβ₅-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with ⁹⁰Y (i.e., RP697) or ¹⁷⁷Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .

Cat. No.	Product Name	Target	Research Area	Image

HY-108831A

Natalizumab (Anti-CD49d) 3 Publications Verification AN100226; BG00002	Integrin	Inflammation/Immunology Cancer
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .

HY-108831

Natalizumab 3 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P704213

	Integrin alpha IV beta 1 Protein, Human (HEK293, His) integrin alpha 4 beta 1 ; ITGA4&ITGB1	Human	HEK293

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

integrin α4β1

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Natural
Products